title: Characterization of cancer stem cell properties of CD24 and CD26-positive human malignant mesothelioma cells.
abstract: Malignant mesothelioma (MM) is an asbestos-related malignancy characterized by rapid growth and poor prognosis. In our previous study, we have demonstrated that several cancer stem cell (CSC) markers correlated with CSC properties in MM cells. Among these markers, we focused on two: CD24, the common CSC marker, and CD26, the additional CSC marker. We further analyzed the CSC properties of CD24 and CD26-positve MM cells. We established RNAi-knockdown cells and found that these markers were significantly correlated with chemoresistance, proliferation, and invasion potentials in vitro. Interestingly, while Meso-1 cells expressed both CD24 and CD26, the presence of each of these two markers was correlated with different CSC property. In addition, downstream signaling of these markers was explored by microarray analysis, which revealed that their expressions were correlated with several cancer-related genes. Furthermore, phosphorylation of ERK by EGF stimulation was significantly affected by the expression of CD26, but not CD24. These results suggest that CD24 and CD26 differentially regulate the CSC potentials of MM and could be promising targets for CSC-oriented therapy.
authors.affiliation: Division of Clinical Immunology, Institute of Medical Science, University of Tokyo, Japan.
authors.forename: Hiroto
authors.initials: H
authors.lastname: Yamazaki
authors.forename: Motohiko
authors.initials: M
authors.lastname: Naito
authors.forename: Farhana Ishrat
authors.initials: FI
authors.lastname: Ghani
authors.forename: Nam H
authors.initials: NH
authors.lastname: Dang
authors.forename: Satoshi
authors.initials: S
authors.lastname: Iwata
authors.forename: Chikao
authors.initials: C
authors.lastname: Morimoto
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D014408:Biomarkers, Tumor / Q000032:analysis / Q000235:genetics / Q000378:metabolism*; D051927:CD24 Antigen / Q000032:analysis / Q000235:genetics / Q000378:metabolism*; D002455:Cell Division / Q000235:genetics; D045744:Cell Line, Tumor; D003630:Daunorubicin / Q000494:pharmacology; D018819:Dipeptidyl Peptidase 4 / Q000032:analysis / Q000235:genetics / Q000378:metabolism*; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D066246:ErbB Receptors / Q000378:metabolism; D005047:Etoposide / Q000494:pharmacology; D015870:Gene Expression; D055785:Gene Knockdown Techniques; D006801:Humans; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000378:metabolism; D018969:Insulin-Like Growth Factor Binding Proteins / Q000378:metabolism; D008654:Mesothelioma / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D009361:Neoplasm Invasiveness; D014411:Neoplastic Stem Cells / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000235:genetics
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D014408:Biomarkers, Tumor; D051927:CD24 Antigen; C515497:IGFBP3 protein, human; D018972:Insulin-Like Growth Factor Binding Protein 3; D018969:Insulin-Like Growth Factor Binding Proteins; D034741:RNA, Small Interfering; C102529:insulin-like growth factor binding protein-related protein 1; D005047:Etoposide; C512478:EGFR protein, human; D066246:ErbB Receptors; D018819:Dipeptidyl Peptidase 4; D003630:Daunorubicin